Emergent BioSolutions to Participate on Vaccine Panel at BIO International Convention 2010

May 3, 2010

ROCKVILLE, Md., May 03, 2010 (BUSINESS WIRE) --Emergent BioSolutions Inc. (NYSE:EBS) announced today that W. James Jackson, Ph.D., the Company's senior vice president and chief scientific officer, will speak on a panel titled "Vaccines for the 21st Century" on May 4 at the BIO International Convention in Chicago, Illinois.

The scientific session, part of the Innovations in Vaccines track, will explore new vaccine technologies and describe new vaccine candidates in development and their potential impact on global health. Other companies expected to present include Merck, Sanofi Pasteur, Vical, and Syntiron.

Event: BIO International Convention
Venue: McCormick Place, Chicago
Emergent Presentation Details: Tuesday, May 4 at 2:00 pm, Room S403B

If media attendees are interested in scheduling a one-on-one interview with Dr. Jackson at this event, please contact Miko Neri at 301.795.1859 or nerim@ebsi.com.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.



SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
+1-301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
+1-301-795-1800
SchmittT@ebsi.com